Six Weeks of Vaginal Estrogen Before Prolapse Surgery: A Tissue Benefit That Hasn't Reached the Outcome That Matters
A biopsy-level finding that the tissue really does improve, set against a bothered patient counting the weeks until her bulge symptoms are actually addressed.
Yolanda F., 68, worked the sales floor at a home-goods store for over twenty years before retiring last spring, and now spends her days looking after her two grandchildren three afternoons a week — work she describes as "more tiring than retail ever was." She has stage 3 apical and anterior pelvic organ prolapse, symptomatic for over a year with a bothersome vaginal bulge she describes feeling by late afternoon most days, along with intermittent difficulty fully emptying her bladder that she manages by repositioning herself while voiding. She has no diabetes, no prior pelvic surgery, and is otherwise in good general health.
She is scheduled for a native-tissue transvaginal apical prolapse repair, and on exam her vaginal epithelium shows the thin, pale changes of postmenopausal atrophy — the finding that has prompted her surgeon to raise six weeks of preoperative vaginal estrogen before the procedure. That recommendation rests on real, biopsy-confirmed evidence: a randomized trial by Rahn and colleagues found that six weeks of preoperative topical estrogen increased mature collagen synthesis, reduced degradative enzyme activity, and increased vaginal wall thickness compared with placebo — a genuine improvement in the tissue substrate a surgeon actually sutures into. What complicates a straightforward recommendation to proceed is that the same research group went on to test the downstream question directly. IMPROVE (Rahn and colleagues, JAMA 2023) randomized postmenopausal women undergoing exactly the operation she is scheduled for — native-tissue transvaginal apical repair — to perioperative vaginal estrogen or placebo, and found no reduction in surgical failure at twelve months, 19% versus 9%, with three-year follow-up unchanged. Her planned procedure is not adjacent to that trial's population; it is that trial's population, which is what makes the gap between the proven tissue-level finding and the absent clinical benefit her gap rather than a general caveat, and what makes the weeks she would spend waiting weeks bought against a result that has already been looked for and not found.
A proven biopsy finding, a trial that looked for the outcome, and six real weeks
I'd start six weeks of vaginal estrogen before we operate. Rahn's trial isn't a soft, theoretical rationale — it's a randomized, biopsy-confirmed finding that preoperative estrogen genuinely increases mature collagen synthesis and vaginal wall thickness compared with placebo. That's the actual tissue we're placing sutures into during her repair, and I want it in the best condition it can be before we start.
I want to be precise about what that finding establishes, because it's being read as settling more than it does — and because the group that produced it has since answered the harder question themselves. IMPROVE, their randomized trial in JAMA in 2023, took postmenopausal women having the same native-tissue apical repair she's scheduled for and gave them perioperative vaginal estrogen or placebo. Surgical failure at twelve months was 19% with estrogen and 9% with placebo — no benefit, and numerically the wrong direction. The tissue-level finding is real. The outcome-level benefit was looked for, in her population, and not found.
I'm not saying don't offer it — I'm saying we shouldn't present six weeks as a proven step toward a better result when the honest answer is that it's proven at the biopsy level and unresolved at hers.
I see her regularly for other things, and I don't think either of you has weighed what six weeks actually costs her day to day. She's living with a bulge she feels by every afternoon and voiding difficulty she's managing by repositioning herself, and that's not a neutral waiting period while a tissue question gets debated. If the clinical benefit has been looked for in her own operation and not found, I think that answer should tip toward what she's actually asking for, which is to be done with this as soon as it's safely possible.
Agreed: proceed directly to surgery without a preoperative estrogen delay, with vaginal estrogen started postoperatively as standard care for her atrophic tissue going forward.
Not agreed: the urogynecologist would still have preferred the preoperative course given the real histologic benefit and considers the decision a reasonable but not clearly correct trade, holding that a single trial powered for surgical failure does not exhaust what better tissue might be doing for her repair; the clinical pharmacologist and primary care physician both consider the decision correct specifically because an intervention without demonstrated outcome benefit should not be allowed to delay a needed, symptom-relieving procedure by default.